Central and Mucosal Immunities are Modified by Non Adsorbable Antibiotic Treatment in Uncomplicated Diverticular Disease

Mini Rev Med Chem. 2015;16(3):218-21. doi: 10.2174/1389557515666150722104035.


We review our experience on Rifaximin in uncomplicated diverticular disease. Our data show that a 2 week treatment induces modifications in the immune system: local mucosal lymphocytes with TLR-4 were increased. In the peripheral blood CD103 cells, which increased before treatment, returned to normal values after Rifaximin.

Publication types

  • Review

MeSH terms

  • Diverticulitis, Colonic / drug therapy*
  • Gastrointestinal Absorption / drug effects
  • Gastrointestinal Microbiome / drug effects
  • Humans
  • Immunity / drug effects
  • Immunity, Mucosal / drug effects
  • Intestinal Mucosa / drug effects
  • Rifamycins / pharmacology
  • Rifamycins / therapeutic use*
  • Rifaximin


  • Rifamycins
  • Rifaximin